Raziel Therapeutics and Fosun Pharma Announce Positive Phase 3 Results for RZL-012 in Submental Fat Reduction, Clearing the Path to a China NDA Filing
Phase 3positiveRZL-012Positive
AI Analysis
Summary
Raziel Therapeutics and Fosun Pharma announced positive Phase 3 results for RZL-012 in submental fat reduction, with a 480-patient pivotal trial meeting all primary and secondary endpoints and showing a 30-percentage-point advantage over placebo. An NDA submission to China's regulator is planned by year-end 2026.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Patients
480
Outcome Details
Pivotal 480-patient trial met all primary and secondary efficacy and safety endpoints after a single treatment cycle with 30-percentage-point advantage in primary responder rate over placebo
Importance:8/10
Sentiment:
0.90
Phase 3Positive ResultsChina NDAPartnershipSubmental Fat Reduction
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 2, 2026 11:00 AM